called initiation. In the second step, promotion, the first clinical manifestations begin
with the formation of benign tumors. Finally, in progression, the tumors become malig-
nant, which in turn can spread to other tissues to form secondary tumors. In the nomen-
clature of cancer, the suffix -oma is appended to a tissue name to denote a benign tumor;
for example, hepatoma and osteoma are benign tumors of the liver and bone, respectively.
Malignant tumors are described using either carcinoma or sarcoma, for mesothelial or
epithelial tumors, respectively. Thus, names for the malignant tumors for liver and bone
are hepatocellular carcinoma and osteosarcoma.
Benign tumors exhibit cellular differentiation and grow by expansion, causing adja-
cent tissues to atrophy. The tumor shows some differentiation and has a clear boundary.
Benign tumor cells appear similar to normal cells under microscopic examination. Benign
tumors are usually not fatal, except when they impinge on critical tissues such as in the
brain. Brain tumors rarely become malignant because they are fatal before reaching that
stage. Benign tumors do not inevitably progress to the next stage, although their clinical
removal obviates that possibility.
Malignant tumors are undifferentiated. Instead of forming a discrete bounded struc-
ture as benign tumors do, they grow invasively into neighboring tissues. Malignant cells
appear obviously deranged. They are capable of the process of metastasis, in which
clumps of mali gnant cells migrate to other tissues through blood and lymph vessels, form-
ing secondary tumors. This rapidly increases the growth of cancerous tissue and accele-
rates the progression of clinical symptoms, especially weakness, a large amount of weight
loss, loss of various bodily functions, and pain.
What accounts for the observed stages of cancer? It is known that genetic damage
is the root cause of cancer. The damage can be either mutations or aberrations. The
latter include chromosome breakage, deletion of chromosome segments, or swapping
of segments between chromosomes. Other evidence, however, suggested involvement
of nongenotoxic agents. For example, when polynuclear aromatic hydrocarbons (PAHs)
are applied to the skin of a mouse, cancer does not occur until followed by application of
another chemical, such as phorbo l esters from croton oil. It does not even matter if the
second application is delayed for up to a year. Clearly, the PAH predisposes the skin
cells to cancer, and the esters stimulate progression to other stages. Furthermore, the
compounds that predispose were often found to be mutagenic, whereas the ones that only
stimulate progression often were not.
Types of Carcinogens The knowledge that carcinogens act by different mechanisms
led to a distinction in two types of carcinogens. The first type are called genotoxic car-
cinogens, which act either themselves or via metabolites to either damage DNA directly
or impair the processes of repair or transcription. This is initiation, as defined above, and
the chemicals are called initiators. Examples include nitrosamines, epoxides, and metals
such as cadmium, chromium, or nickel. The direct-acting genotoxins are often electro-
philic compounds that bind to DNA, similar to the action of mutagens. Others must be
biotransformed to be genotoxic and are called precarcinogens. Most genotoxic environ-
mental pollutants are in this category, including chlorinated hydrocarbons, aromatics such
as benzene, and PAHs. The mechanism for carcinogenic metals, such as arsenic, chro-
mium, and nickel, is not understood. They are thoug ht to impair DNA replication or
transcription by complexing with the DNA or associated proteins. Several nonchemical
carcinogens act by changing the cellular DNA and therefore may be classified as geno-
toxic. These include ionizing radiation and certain viruses.
716 THE SCIENCE OF POISONS